HUMIRA Market Drug Insight and Market Forecast - 2032

“HUMIRA Market Drug Insight and Market Forecast - 2032” report provides comprehensive insights about HUMIRA for Ulcerative Colitis (UC) in the seven major markets. A detailed picture of the HUMIRA for ulcerative colitis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the HUMIRA for ulcerative colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the HUMIRA market forecast analysis for ulcerative colitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ulcerative colitis.

Drug Summary

Adalimumab is a tumor necrosis factor blocker. Adalimumab is a recombinant human IgG1 monoclonal antibody created using phage display technology resulting in an antibody with human-derived heavy and light chain variable regions and human IgG1 constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary (CHO)) expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilo Daltons. HUMIRA (adalimumab) injection is supplied as a sterile, preservative-free solution for subcutaneous administration. It is currently approved by the US FDA to treat both CD and UC, among a few other indications.

Dosage
The recommended HUMIRA dose regimen for adult patients with UC is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29), continue with a dose of 40 mg every other week. HUMIRA should be continued only in patients who have shown evidence of clinical remission by 8 weeks (Day 57) of therapy. Aminosalicylates and/or corticosteroids may be continued during treatment with HUMIRA. Azathioprine and 6-mercaptopurine (6-MP) may be continued during treatment with HUMIRA if necessary.

Mechanism of Action

Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine involved in normal inflammatory and immune responses. Elevated levels of TNF are found in the synovial fluid of patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of the diseases. The relationship between these pharmacodynamic activities and the mechanism(s) by which HUMIRA exerts its clinical effects is unknown. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1-2 × 10-10 M).

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the HUMIRA description, mechanism of action, dosage and administration, research and development activities in ulcerative colitis.
• Elaborated details on HUMIRA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the HUMIRA research and development activities in ulcerative colitis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around HUMIRA.
• The report contains forecasted sales of for ulcerative colitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ulcerative colitis.
• The report also features the SWOT analysis with analyst views for HUMIRA in ulcerative colitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HUMIRA Analytical Perspective

In-depth HUMIRA Market Assessment

This report provides a detailed market assessment of HUMIRA for ulcerative colitis in the seven major markets, i.e., United States, EU4 (Germany, France, Italy, Spain), the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

HUMIRA Clinical Assessment

The report provides the clinical trials information of HUMIRA for ulcerative colitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for ulcerative colitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HUMIRA dominance.
• Other emerging products for ulcerative colitis are expected to give tough market competition to HUMIRA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HUMIRA in ulcerative colitis.
• This in-depth analysis of the forecasted sales data of HUMIRA from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HUMIRA in ulcerative colitis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of HUMIRA?
• What is the clinical trial status of the study related to HUMIRA in ulcerative colitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HUMIRA development?
• What are the key designations that have been granted to HUMIRA for ulcerative colitis?
• What is the forecasted market scenario of HUMIRA for ulcerative colitis?
• What are the forecasted sales of HUMIRA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to HUMIRA for ulcerative colitis?
• Which are the late-stage emerging therapies under development for the treatment of ulcerative colitis?

This product will be delivered within 2 business days.